GENE ONLINE|News &
Opinion
Blog

2022-05-27| Trials & Approvals

Janssen’s First Cell Therapy Gets Europe’s Approval for Multiple Myeloma

by Fujie Tham
Share To

Janssen’s first cell therapy – Carvykti, was granted conditional marketing authorization for treatment of adults with relapsed and refractory multiple myeloma (RRMM) by the European Commission (EC). The therapeutic developed jointly with China-based Legend Biotech was approved by the FDA earlier in February in the US.

Multiple myeloma is a rare cancer of blood plasma cells, a type of white blood cell that manufactures antibodies and is found in the bone marrow. In multiple myeloma, proliferation of plasma cells is unregulated, causing abnormal, immature plasma cells to multiply and fill up the bone marrow spaces. When plasma cells turn cancerous, they no longer protect the body and produce abnormal proteins that can cause issues affecting the kidneys, bones, or blood.

Related article: J&J, Legend’s Cell Therapy Gets FDA Nod 

Addressing Unmet Needs for New Multiple Myeloma Treatments

 

Carvykti’s active ingredient is ciltacabtagene autoleucel, a genetically modified autologous T cell immunotherapy consisting of modified T-cells bearing a chimeric antigen receptor (CAR) that targets B cell maturation antigen (BCMA). BCMA is expressed primarily on the surface of malignant multiple myeloma B-lineage cells, late-stage B cells, and plasma cells. Upon binding to BCMA-expressing cells, the CAR promotes T cell activation, expansion, and the elimination of cancerous cells.

As there is no cure for multiple myeloma, there is an urgent demand for Carvykti. Patients who already received immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies, have recurring disease, or stopped responding to previous treatments can now be treated with a different approach. 

The pharma giant projected peak annual sales of Carvykti to exceed $5 billion. Based on a deal inked in 2017, Johnson & Johnson and Legend will divide the profits 30-70 in China and 50-50 in all other countries. Carvykti is currently under review in Japan, while Legend Biotech secured a breakthrough therapy designation in China, the first product to be granted such a label.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
2024-03-01
FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences
2024-01-24
JPM 2024: Biotech Companies Mapping Out Their Future, and a New Round of M&A Spree Begins
2024-01-09
LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top